178 related articles for article (PubMed ID: 31634188)
1. Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings.
Gandhi M; Wang G; King R; Rodrigues WC; Vincent M; Glidden DV; Cressey TR; Bacchetti P; Spinelli MA; Okochi H; Siriprakaisil O; Klinbuayaem V; Mugo NR; Ngure K; Drain PK; Baeten JM
AIDS; 2020 Feb; 34(2):255-260. PubMed ID: 31634188
[TBL] [Abstract][Full Text] [Related]
2. Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test.
Gandhi M; Bacchetti P; Spinelli MA; Okochi H; Baeten JM; Siriprakaisil O; Klinbuayaem V; Rodrigues WC; Wang G; Vincent M; Cressey TR; Drain PK
J Acquir Immune Defic Syndr; 2019 May; 81(1):72-77. PubMed ID: 30664078
[TBL] [Abstract][Full Text] [Related]
3. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
[TBL] [Abstract][Full Text] [Related]
4. Perspectives on the utility and interest in a point-of-care urine tenofovir test for adherence to HIV pre-exposure prophylaxis and antiretroviral therapy: an exploratory qualitative assessment among U.S. clients and providers.
Bardon AR; Simoni JM; Layman LM; Stekler JD; Drain PK
AIDS Res Ther; 2020 Aug; 17(1):50. PubMed ID: 32762713
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir Urine Assay to Monitor Adherence to HIV Pre-exposure Prophylaxis.
Moorthy GS; Lalley-Chareczko L; Koenig HC; Zuppa AF
Curr Clin Pharmacol; 2020; 15(2):102-104. PubMed ID: 31713497
[TBL] [Abstract][Full Text] [Related]
6. Brief Report: High Accuracy of a Real-Time Urine Antibody-Based Tenofovir Point-of-Care Test Compared With Laboratory-Based ELISA in Diverse Populations.
Spinelli MA; Rodrigues WC; Wang G; Vincent M; Glidden DV; Okochi H; Stalter R; Defechereux P; Deutsch M; Grant RM; Ngure K; Mugo NR; Baeten JM; Gandhi M;
J Acquir Immune Defic Syndr; 2020 Jun; 84(2):149-152. PubMed ID: 32167963
[TBL] [Abstract][Full Text] [Related]
7. Point-of-care semi-quantitative test for adherence to tenofovir alafenamide or tenofovir disoproxil fumarate.
Sevenler D; Niu X; Dossantos S; Toner M; Cressey TR; Sandlin RD; Drain PK
J Antimicrob Chemother; 2022 Mar; 77(4):996-999. PubMed ID: 35038336
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing.
Else LJ; Dickinson L; Edick S; Zyhowski A; Ho K; Meyn L; Dilly-Penchala S; Thompson B; Shaw V; Khoo S; Brand RM
J Antimicrob Chemother; 2024 Jul; 79(7):1597-1605. PubMed ID: 38758205
[TBL] [Abstract][Full Text] [Related]
9. Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence.
Gandhi M; Bacchetti P; Rodrigues WC; Spinelli M; Koss CA; Drain PK; Baeten JM; Mugo NR; Ngure K; Benet LZ; Okochi H; Wang G; Vincent M
EClinicalMedicine; 2018; 2-3():22-28. PubMed ID: 30906930
[TBL] [Abstract][Full Text] [Related]
10. Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a preexposure prophylaxis demonstration project.
Spinelli MA; Glidden DV; Rodrigues WC; Wang G; Vincent M; Okochi H; Kuncze K; Mehrotra M; Defechereux P; Buchbinder SP; Grant RM; Gandhi M
AIDS; 2019 Apr; 33(5):867-872. PubMed ID: 30649051
[TBL] [Abstract][Full Text] [Related]
11. Urine tenofovir testing for real-time PrEP adherence feedback: a qualitative study involving transgender women in Uganda.
Mujugira A; Karungi B; Mugisha J; Nakyanzi A; Nampewo O; Naddunga F; Kamusiime B; Nsubuga R; Nyanzi KR; Muwonge TR; Wyatt MA; Ware NC; Gandhi M; Haberer JE
J Int AIDS Soc; 2024 May; 27(5):e26255. PubMed ID: 38695107
[TBL] [Abstract][Full Text] [Related]
12. Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
Haaland RE; Martin A; Livermont T; Fountain J; Dinh C; Holder A; Lupo LD; Hall L; Conway-Washington C; Kelley CF
J Acquir Immune Defic Syndr; 2019 Nov; 82(3):252-256. PubMed ID: 31335590
[TBL] [Abstract][Full Text] [Related]
13. Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide.
Lalley-Chareczko L; Hiserodt E; Moorthy G; Zuppa A; Mounzer K; Koenig H
Front Pharmacol; 2020; 11():286. PubMed ID: 32265700
[No Abstract] [Full Text] [Related]
14. A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study.
Cressey TR; Siriprakaisil O; Klinbuayaem V; Quame-Amaglo J; Kubiak RW; Sukrakanchana PO; Than-In-At K; Baeten J; Sirirungsi W; Cressey R; Drain PK
BMC Infect Dis; 2017 Jul; 17(1):496. PubMed ID: 28705153
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy of a point-of-care urine tenofovir assay, and associations with HIV viraemia and drug resistance among people receiving dolutegravir and efavirenz-based antiretroviral therapy.
Dorward J; Lessells R; Govender K; Moodley P; Samsunder N; Sookrajh Y; Turner P; Butler CC; Hayward G; Gandhi M; Drain PK; Garrett N
J Int AIDS Soc; 2023 Sep; 26(9):e26172. PubMed ID: 37735860
[TBL] [Abstract][Full Text] [Related]
16. Determining the acceptability of point-of-care urine tenofovir testing and its performance in predicting HIV RNA suppression.
Marryshow TA; Muhairwe J; Tang A; Molulela MMM; Matta R; Jordan MR
Int J STD AIDS; 2022 Jul; 33(8):777-783. PubMed ID: 35611960
[TBL] [Abstract][Full Text] [Related]
17. Brief Report: No Difference in Urine Tenofovir Levels in Patients Living With HIV on Unboosted Versus Dose-Adjusted Boosted Tenofovir Alafenamide.
Johnson KA; Okochi H; Glidden DV; Gandhi M; Spinelli M
J Acquir Immune Defic Syndr; 2021 Sep; 88(1):57-60. PubMed ID: 33990489
[TBL] [Abstract][Full Text] [Related]
18. Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate.
Cressey TR; Siriprakaisil O; Kubiak RW; Klinbuayaem V; Sukrakanchana PO; Quame-Amaglo J; Okochi H; Tawon Y; Cressey R; Baeten JM; Gandhi M; Drain PK
Int J Infect Dis; 2020 Aug; 97():365-370. PubMed ID: 32553717
[TBL] [Abstract][Full Text] [Related]
19. Challenges to PrEP use and perceptions of urine tenofovir adherence monitoring reported by individuals on PrEP.
Hunt T; Lalley-Chareczko L; Daughtridge G; Swyryn M; Koenig H
AIDS Care; 2019 Oct; 31(10):1203-1206. PubMed ID: 30821473
[TBL] [Abstract][Full Text] [Related]
20. Point-of-care urine tenofovir monitoring of adherence to drive interventions for HIV treatment and prevention.
Spinelli M; Gandhi M
Expert Rev Mol Diagn; 2024 Mar; 24(3):169-175. PubMed ID: 38353417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
